Welcome to our dedicated page for Vtv Therapeutics news (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on Vtv Therapeutics stock.
vTv Therapeutics Inc. reports developments as a late-stage biopharmaceutical company focused on oral, small-molecule drug candidates for diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a liver-selective glucokinase activator being investigated as an oral adjunctive therapy to insulin for type 1 diabetes. Company updates also reference development work and partnerships across additional chronic-disease candidates, including the PDE4 inhibitor HPP737.
Recurring announcements include clinical and regulatory updates for cadisegliatin, financial results and corporate updates, license and collaboration activity, investor-conference participation, and Nasdaq inducement grants under equity compensation plans. News about vTv often connects pipeline progress with funding arrangements, intellectual property, and business-development agreements that support its drug-development strategy.
vTv Therapeutics (Nasdaq: VTVT) announced positive results from the Phase 2 Simplici-T1 study for TTP399, an oral adjunctive therapy for type 1 diabetes (T1D). Data indicated that TTP399 does not raise the risk of diabetic ketoacidosis (DKA) and leads to significant reductions in HbA1c without increasing hypoglycemia risk. These findings support further development of TTP399, with plans for a pivotal study expected by end of 2020. The study was presented at the European Association for the Study of Diabetes Annual Meeting.
vTv Therapeutics has appointed Edward P. Taibi, Executive Vice President at MacAndrews & Forbes, to its Board of Directors, effective August 31, 2020. This strategic move aims to enhance the company's leadership as it pursues its clinical drug development pipeline targeting type 1 diabetes and Alzheimer’s disease. Mr. Taibi brings extensive experience in business leadership and capital markets from his previous roles. MacAndrews has a significant investment history in vTv, impacting its business strategies.
vTv Therapeutics Inc. (Nasdaq: VTVT) reported its second-quarter 2020 financial results, showing significant progress in advancing its TTP399 drug for type 1 diabetes, with upcoming pivotal studies planned by year-end. The firm is also actively enrolling patients for its Alzheimer's treatment study, despite COVID-19 challenges.
Financially, cash reserves increased to $6.4 million, while R&D expenses decreased to $2.5 million. The net loss for the quarter was $5.0 million, an improvement from the previous quarter's $7.2 million loss. Revenue remained negligible, reflecting ongoing developmental focus.
vTv Therapeutics (Nasdaq: VTVT) announced its participation in the 2020 Alzheimer's Association International Conference (AAIC) from July 27-31, 2020. The company will present a poster showcasing analyses from the STEADFAST Study of azeliragon, which examines its effects on cognitive functions in Alzheimer's patients with type 2 diabetes. The presentation is scheduled for July 29, 2020, at 5:00 pm CT. The STEADFAST study consists of two Phase 3 trials investigating azeliragon's safety and efficacy as a treatment for mild Alzheimer's disease.
vTv Therapeutics (Nasdaq: VTVT) presented positive data from the Phase 2 Simplici-T1 Study at the American Diabetes Association’s 80th Scientific Sessions. The trial demonstrated that TTP399, a once-daily oral treatment, significantly reduced HbA1c levels by 0.3% compared to placebo (p<0.01), without increasing the risk of hypoglycemia or diabetic ketoacidosis. The study involved 85 subjects, confirming promising results from prior phases. TTP399 may provide a valuable adjunctive therapy for type 1 diabetes patients, aiming to enhance glucose control while minimizing insulin requirements.
vTv Therapeutics (Nasdaq: VTVT) has announced that two late-breaking abstracts showcasing TTP399 as an oral adjunctive therapy for type 1 diabetes will be virtually presented at the American Diabetes Association’s 80th Scientific Sessions from June 12–16, 2020. The Phase 2 (Part 2) Simplici-T1 trial showed TTP399's positive impact on lowering HbA1c, reducing insulin dosage, and increasing Time in Range in T1D patients. The trial's presentations on June 13 will provide further data supporting these findings.
vTv Therapeutics Inc. (Nasdaq: VTVT) will hold its 2020 Annual Meeting of Stockholders on June 11, 2020, at 9:00 a.m. EDT in a virtual format due to COVID-19 safety concerns. Stockholders must register by June 9, 2020, at 5:00 p.m. EDT to attend the meeting and may submit questions during registration. The company encourages all stockholders to vote in advance of the meeting using the proxy materials previously distributed. vTv is a clinical-stage biopharmaceutical company focused on developing drug candidates for diabetes, Alzheimer’s disease, and inflammatory disorders.
vTv Therapeutics Inc. (Nasdaq:VTVT) released its Q1 2020 financial results, reporting a net loss of $7.2 million with a net loss per share of $0.11. The cash position decreased to $2.9 million from $4.3 million in Q4 2019, indicating financial strain. Despite challenges posed by COVID-19, the company is advancing its clinical trials for TTP399 and azeliragon. Notably, they are engaging with the FDA on a pivotal study for TTP399 and are sustaining patient enrollment for the Elevage study of azeliragon. Financial flexibility was improved through loan amendments and an ATM offering of up to $13 million.